Stock Analysis
Halozyme Therapeutics, Inc.HALO
P/E 33.44×· 5Y range 11.47–39.69×· top 5% of history
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy16 analystsP/E 33.4× sits at the 95th percentile of its 5.059548254620124-year history.
Cash covers 11% of debt · Q2 2026.
PMP Verdict
High quality, but expensive
Strengths
- Profitability95
- Financial Health75
Risks
- Valuation37
- Growth50
Excellent business. Weak entry price.
Bull Case
- ✓Altman Z 4.9 — safe-zone balance sheet
- ✓ROE 288.1% — efficient capital deployment
- ✓Revenue CAGR 33.2% — durable top-line growth
- ✓Interest coverage 21.2× — debt well covered
What's happening with HALO
Profile
Strong profitability and financial health; valuation and moat lag behind.
How is each axis scored?
- Valuation37/100 · Weak
- P/E vs own history (95th pct)0/25
- FCF yield (5.9%)20/25
- P/S (8.3x)12/25
- EV/EBIT (26.3x)5/25
- Growth50/100 · Moderate
- Revenue CAGR (33.2%)25/25
- Net income CAGR (-5.8%)0/25
- EPS CAGR 5Y (-1.7%)0/25
- Fwd implied growth (191.5%)25/25
- Profitability95/100 · Strong
- ROIC (22.6%)20/25
- ROE (288.1%)25/25
- Net margin (24.9%)25/25
- Operating margin (35.9%)25/25
- Financial Health75/100 · Strong
- Altman Z (4.95)25/25
- Current ratio (2.71)25/25
- Interest coverage (21.2x)25/25
- Net cash / debt (D/A 76%)0/25
- Quality65/100 · Moderate
- Piotroski F (5/9)15/25
- Beneish M (-3.15)25/25
- FCF conversion (195%)25/25
- Margin stability (σ 49.4%)0/25
- Moat48/100 · Weak
- ROIC >12% years (6/9 yrs)13/25
- Median gross margin (82.6%)25/25
- FCF-positive years (7/10 yrs)10/25
- Worst-year net margin (worst -70.2%)0/25
Risk Flags
- ⚠3 loss-making years in recent history
- ⚠P/E 33.4× at top 5% of 5-year history
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. Show more
The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Headquarters: SAN DIEGO, CA · Employees: 423 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
37DP/E (TTM)33.3xC
Grade C: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 11.5x–39.7x · 95th pct
P/FCF22.8xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield5.9%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 2.5%–9.4% · 50th pct
P/S (TTM)8.28xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 5.1x–15.1x · 66th pct
EV/EBIT26.3xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 11.0x–38.5x · 86th pct
EV/Sales9.3xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E11.4xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio96.00xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.08B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
95A+ROIC22.6%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE288.1%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA16.6%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin24.9%A
Grade A: HighNet Income / Revenue
Operating Margin35.9%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin82.4%A
Grade A: PremiumGross Profit / Revenue
FCF Margin48.5%A
Grade A: HighFCF / Revenue
True FCF Margin44.7%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
50CRevenue CAGR33.2%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-5.8%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-1.7%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth191.5%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)-23.4%A
Grade A: BuybacksShare count change over 5Y
SBC / Net Income15.2%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue3.8%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
75B+Altman Z-Score4.95A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.71xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio1.99xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage21.2xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment2.4yA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT3.3xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity15.18xD
Grade D: HighDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.11xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
65BPiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-3.15A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion194.9%A
Grade A: StrongFCF / Net Income
Margin Stability49.4%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue0.7%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.67xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Torley Helen Filed | Torley Helen | Option exercise | -20000 | |
Torley Helen Filed | Torley Helen | SellOpen market sale | -200 | |
Torley Helen Filed | Torley Helen | SellOpen market sale | -11900 | |
Torley Helen Filed | Torley Helen | SellOpen market sale | -3090 | |
Torley Helen Filed | Torley Helen | SellOpen market sale | -4810 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Torley Helen Filed | Torley Helen | Option exercise | +20.0K | |
Torley Helen Filed | Torley Helen | Option exercise | -20000 | |
Torley Helen Filed | Torley Helen | SellOpen market sale | -200 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
48D+ROIC >12% Years6/9 yrsC
Grade C: ModerateShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)82.6%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years7/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-70.2%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$3.64
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$2.03
Cash & short-term investments per share (Finnhub)
Book Value / Share$1.26
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$2.18B
Total debt obligations (short + long term)
Cash & Equiv.$231.00M
Cash and short-term investments
Net Debt$1.95B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$143.54M
Shareholders' equity (book value)
Asset / Liability1.06xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$13.78B
Current Market Capitalization
Beta0.94B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Halozyme Therapeutics, Inc. (HALO)
Piotroski F-Score of 5/9 indicates mixed fundamentals for Halozyme Therapeutics, Inc.. Altman Z-Score of 4.95 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -3.15 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 33% annually — a strong growth profile.
- Halozyme Therapeutics, Inc. converts about 48% of revenue into free cash flow — strong cash generation.
- Takes ~2.4 years to repay net debt from free cash flow.
- Halozyme Therapeutics, Inc. posted a net loss in 3 of 10 available completed fiscal years (2016–2025).
- Return on equity of 288.1% is well above the market average.
See how HALO ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all HALO moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 14 | Regular | 116.69 | +6.45% | 3.46 |
| Oct 14 | After-hours | 117.40 | +7.10% | 3.80 |
| Sep 22 | After-hours | 115.69 | +3.80% | 2.73 |
Frequently Asked Questions about HALO
What is the current Halozyme Therapeutics, Inc. (HALO) stock price?
HALO is trading at $121.84 at the last market close, up 0.27% on the session. PreMarketPrice tracks HALO pre-market, intraday and after-hours prices.
Is HALO stock a buy right now?
PreMarketPrice's quantitative model rates Halozyme Therapeutics, Inc.'s financial health at 75/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is HALO stock overvalued?
Halozyme Therapeutics, Inc. trades at a trailing P/E of 33.3 and our valuation score rates it 37/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Halozyme Therapeutics, Inc. report earnings?
No confirmed earnings date is currently scheduled for HALO. The Earnings section lists recent reports and updates as dates are announced.
What sector does Halozyme Therapeutics, Inc. operate in?
Halozyme Therapeutics, Inc. operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Halozyme Therapeutics, Inc. do?
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies.
About Halozyme Therapeutics, Inc. (HALO) Stock
Halozyme Therapeutics, Inc. (HALO) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Halozyme Therapeutics, Inc. is trading at $121.84, up 0.27% on the day with a market capitalization of $13.8 billion. The financial health score for HALO is 75/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for HALO stock.
HALO Stock Analysis & Key Metrics
On PreMarketPrice, you can track Halozyme Therapeutics, Inc. (HALO) across multiple dimensions:
- Pre-market price & movement: Real-time HALO stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for HALO with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Halozyme Therapeutics, Inc. across multiple reporting periods.
- Financial health score: A composite score of 75/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for HALO.
- Sector peers: Compare HALO against 5 other healthcare stocks on key financial metrics.
Is HALO a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Halozyme Therapeutics, Inc. (HALO) as an investment. The financial health score of 75/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Halozyme Therapeutics, Inc. (HALO) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.